       Document 0666
 DOCN  M9630666
 TI    Prolonged survival of mice with glioma injected intracerebrally with
       double cytokine-secreting cells.
 DT    9603
 AU    Lichtor T; Glick RP; Kim TS; Hand R; Cohen EP; Division of Neurosurgery,
       Cook County Hospital, Chicago,; Illinois, USA.
 SO    J Neurosurg. 1995 Dec;83(6):1038-44. Unique Identifier : AIDSLINE
       MED/96086871
 AB    A novel approach toward the treatment of glioma was developed in a
       murine model. The genes for both interleukin-2 (IL-2) and
       interferon-gamma (IFN-gamma) were first transfected into a mouse
       fibroblast cell line that expresses defined major histocompatibility
       complex (MHC) determinants (H-2k). The double cytokine-secreting cells
       were then cotransplanted intracerebrally with the Gl261 murine glioma
       cell line into syngeneic C57BL/6 mice (H-2b) whose cells differed at the
       MHC from the cellular immunogen. The results indicate that the survival
       of mice with glioma injected with the cytokine-secreting allogeneic
       cells was significantly prolonged, relative to the survival of mice
       receiving equivalent numbers of glioma cells alone. Using a standard
       51Cr-release assay, the specific release of isotope from labeled Gl261
       cells coincubated with spleen cells from mice injected intracerebrally
       with the glioma cells and the cytokine-secreting fibroblasts was
       significantly higher than the release of isotope from glioma cells
       coincubated with spleen cells from nonimmunized mice. The cellular
       antiglioma response was mediated by natural killer/lymphokine-activated
       killer and Lyt-2.2+ (CD8+) cells. The increased survival of mice with
       glioma and the specific immunocytotoxic responses after immunization
       with fibroblasts modified to secrete both IL-2 and IFN-gamma indicate
       the potential of an immunotherapeutic approach to gliomas with
       cytokine-secreting cells.
 DE    Animal  Brain Neoplasms/MORTALITY/*THERAPY  Cell Line  Cytotoxicity,
       Immunologic  CD8-Positive T-Lymphocytes/IMMUNOLOGY  Disease Models,
       Animal  Female  Fibroblasts/*SECRETION/TRANSPLANTATION
       Glioma/MORTALITY/*THERAPY  Interferon Type II/*SECRETION/THERAPEUTIC USE
       Interleukin-2/*SECRETION/THERAPEUTIC USE  Killer Cells,
       Lymphokine-Activated/IMMUNOLOGY  Killer Cells, Natural/IMMUNOLOGY  Mice
       Mice, Inbred C57BL  Spleen/CYTOLOGY/IMMUNOLOGY  Support, U.S. Gov't,
       P.H.S.  Time Factors  Transfection  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

